

Eligibility criteria for prognostic breast gene testing

Southern Cross will only reimburse the cost of prognostic breast gene testing under a member's policy when criteria **1, 2, 3 and 4** below are met for that member.

1. Have a high clinical risk of recurrence of breast cancer according to clinical-pathological criteria that is eligible for chemotherapy (defined in MINDACT as 'high risk').
2. Member must have had histologically confirmed early invasive breast cancer with:
 - T1 / T2 / operable T3 disease
 - 0-3 positive lymph nodes
 - unilateral tumour (multifocal allowed if same histology; DCIS / LCIS allowed).
3. Member must have undergone breast-conserving surgery / mastectomy with either sentinel node procedure or full axillary clearance (if breast conserving surgery, must undergo radiotherapy); unresectable positive deep margins allowed with radiotherapy if all other margins negative.
4. WHO performance status 0-1 (Karnofsky scale ≥ 70)

Please also ensure you are familiar with all **policy exclusions**, including:

- Acute care
- Congenital conditions
- Cosmetic treatment/procedures
- Health screening
- Treatment of any condition not detrimental to health
- Unapproved healthcare services.

Refer to the relevant policy document for specific conditions and exceptions that apply to these exclusions.